High platelet reactivity persists in many patients receiving antiplatelet therapy for secondary prevention of ischaemic stroke. Patient-tailored antiplatelet therapy, guided by platelet function tests, is an appealing approach for prevention of recurrent vascular events. However, a recent study has demonstrated that this strategy is associated with worse clinical outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Snoep, J. D., Hovens, M. M., Eikenboom, J. C., van der Bom, J. G. & Huisman, M. V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167, 1593–1599 (2007).
Schwammenthal, Y. et al. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc. Dis. 25, 355–361 (2008).
Snoep, J. D. et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221–231 (2007).
Combescure, C. et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J. Thromb. Haemost. 8, 923–933 (2010).
Depta, J. P. et al. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. Stroke http://dx.doi.org/10.1161/STROKEAHA.112.655084.
Reny, J. L. et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the antiplatelet drug resistances and ischemic events study. Circulation 125, 3201–3210 (2012).
Pettersen, A.-Å ., Seljeflot, I., Abdelnoor, M. & Arnesen, H. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J. Am. Heart Assoc. 1, e000703 (2012).
Price, M. J. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097–1105 (2011).
Diener, H. C. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364, 331–337 (2004).
Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Tanne, D. Secondary stroke prevention—personalized antiplatelet therapy. Nat Rev Neurol 8, 536–537 (2012). https://doi.org/10.1038/nrneurol.2012.180
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.180
